MediWound to Present at the 45th Annual TD Cowen Health Care Conference

Company Overview - MediWound Ltd. is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair [3] - The company specializes in the development, production, and commercialization of innovative biologics that enhance existing standards of care, improve patient experiences, and reduce healthcare costs [3] Product Pipeline - MediWound's first drug, NexoBrid, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for surgical interventions [4] - The company is advancing EscharEx, a promising candidate currently in Phase III development for the debridement of chronic wounds, which has shown distinct advantages over the currently available $375+ million drug for wound debridement in Phase II clinical trials [4] Upcoming Events - CEO Ofer Gonen will present a corporate overview at the 45th Annual TD Cowen Health Care Conference on March 5, 2025, at 11:50 AM ET [1] - The management team will host one-on-one meetings during the conference, encouraging interested investors to contact their TD Cowen representative to schedule a meeting [2]